Evidence map›Paper›PMID 41833859›Full record

ArticleNeurobiology of disease2026

Tunable tau expression in C. elegans neurons reveals that early-AD tau phosphorylation selectively impacts behavior and mitochondrial quality control.

T Carroll, D Pfendler, H Alhaj Arhayem, R Thoma, A Müller-Eigner, A Straut, G V W Johnson, K Nehrke

Abstract read
In one paragraph

Article in Neurobiology of disease, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

8 authors.

T CarrollUniversity of Rochester School of Medicine and Dentistry, Department of Pathology and Laboratory Medicine, United States of America. Electronic address: Trae_Carroll@urmc.rochester.edu.
D PfendlerUniversity of Rochester School of Medicine and Dentistry, Department of Anesthesiology and Perioperative Medicine, United States of America.
H Alhaj ArhayemUniversity of Rochester School of Medicine and Dentistry, Department of Medicine, Nephrology Division, United States of America.
R ThomaUniversity of Rochester School of Medicine and Dentistry, Department of Medicine, Nephrology Division, United States of America.
A Müller-EignerUniversity of Rochester School of Medicine and Dentistry, Department of Anesthesiology and Perioperative Medicine, United States of America.
A StrautUniversity of Rochester School of Medicine and Dentistry, Department of Toxicology, United States of America.
G V W JohnsonUniversity of Rochester School of Medicine and Dentistry, Department of Anesthesiology and Perioperative Medicine, United States of America. Electronic address: Gail_Johnsonvoll@urmc.rochester.edu.
K NehrkeUniversity of Rochester School of Medicine and Dentistry, Department of Medicine, Nephrology Division, United States of America. Electronic address: Keith_Nehrke@urmc.rochester.edu.

Funding

VISUAL INDICES OF NEUROTOXICITYP30ES001247 · NIEHS · UNIVERSITY OF ROCHESTER · PI Sally W Thurston · 1985 to 2026
$42.8M
Training in Environment ToxicologyT32ES007026 · NIEHS · UNIVERSITY OF ROCHESTER · PI Alison Elder, Marissa Sobolewski Terry · 1985 to 2026
$20.2M
Mitochondrial ROS Microdomains and Neuronal IschemiaR01NS092558 · NINDS · UNIVERSITY OF ROCHESTER · PI WOJTOVICH, ANDREW PHILLIP · 2015 to 2025
$3.7M
Tau Post-Translational Modifications and Mitochondrial Quality ControlR01AG067617 · NIA · UNIVERSITY OF ROCHESTER · PI JOHNSON, GAIL V. W., NEHRKE, KEITH · 2020 to 2024
$2.9M
T32 University of Rochester Aging and Alzheimer's disease Training ProgramT32AG076455 · NIA · UNIVERSITY OF ROCHESTER · PI M. KERRY O'BANION · 2022 to 2026
$1.5M
NIA NIH HHS R01 AG067617NIA NIH HHS T32 AG076455NIEHS NIH HHS P30 ES001247NIEHS NIH HHS T32 ES007026NINDS NIH HHS R01 NS092558
6 · The paper itself

Abstract

Tau protein accumulates myriad post-translational modifications as Alzheimer's disease (AD) progresses, and early-disease tau modifications such as phosphorylation at threonine 231 (T231) likely play a key role in AD pathogenesis. Here, a series of "tunable tau" strains was developed in C. elegans to test the relative impact of tau pseudo-phosphorylation of T231 (T231E) compared to protein expression level as a driver of phenotypic penetrance and severity. Multiple copies of a cassette coding for pan-neuronal wildtype tau or T231E were inserted at a genomic safe harbor loci to create a repertoire of strains expressing tau from low to high levels. In stereotypical behavioral assays of locomotory activity, T231E selectively impacted phenotypic severity compared to wild-type human tau controls, which further tracked with age and tau expression level. However, deficits in associative memory were non-selective between tau and T231E. Moreover, genetic, pharmacologic, and molecular approaches indicated that mitophagy modulation could suppress T231E phenotypes. Additionally, a robust mitochondrial unfolded protein response (UPRmt) occurred in T231E, and loss of atfs-1, a transcription factor central to the UPRmt suppressed T231E toxicity. These results demonstrate that phenotypic severity is invariably associated with tau dosage, while early-AD relevant modifications can be causative drivers of selective deficits. Consistent with recent findings, enhancing mitophagy or suppressing potentially maladaptive consequences of persistent UPRmt induction can be beneficial. This provides a solid foundation for further interrogation into mitochondrial quality control disruption as a potential root cause for AD pathogenesis.

Indexed as

Alzheimer DiseaseBehavior, AnimalMitochondriaNeuronstau ProteinsAnimalsAnimals, Genetically ModifiedCaenorhabditis elegansCaenorhabditis elegans ProteinsHumansPhosphorylationUnfolded Protein ResponseCaenorhabditis elegans Proteinstau ProteinsAlzheimer's diseaseAuxin inducible degronC. elegansMitochondrial quality controlMitochondrial unfolded protein responsePhosphorylationTau

Identifiers

PMID41833859
PMCPMC13129564

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.